Speaker Profile
Ph.D., Distinguished Scientist, Genentech
Biography
Lélia Delamarre joined the Cancer Immunology Department at Genentech after completing her postdoctoral training at Yale University where she studied the cell biology of antigen presentation in dendritic cells. She obtained a PhD in Virology from Université Pierre et Marie Curie in France. Her laboratory studies the modulation of dendritic cell and T cell functions, with the goal of developing new strategies to enhance immune responses to cancer.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair: Ira Mellman, Medici Therapeutics
PMWC Award Ceremony
• Jedd D. Wolchok, Weill Cornell Medicine
• Suzanne Topalian, Johns Hopkins
• Levi Garraway, Roche
Targeting the Tumor Microenvironment (TME) in Practice: Biomarkers & Combos
• Chair: Ira Mellman, Medici Therapeutics
• Dmitry Gabrilovich, AstraZeneca
Immunotherapy with Personalized Cancer Vaccines: Who, When, How Fast?
• Chair: Suzanne Topalian, Johns Hopkins
• Tal Zaks, Orbimed
• Lelia Delamarre, Genentech
ADCs in the Checkpoint Era: Who Benefits, What to Combine, What to Avoid
• Chair: Shreya Badhrinarayanan, Pfizer
• S. Peter Kang, Daiichi Sankyo
Strategic IP Management in Cell and Gene Therapy: Navigating Legal and Practical Challenges
• Janet Xiao, Morrison & Foerster LLP
Checkpoint 2.0 in Practice: PD-1+VEGF Wins, Resistance Salvage & Biomarker Gates
• Chair: Jedd D. Wolchok, Weill Cornell Medicine
Future Breakthroughs in Immuno-Oncology: New Targets, Modalities & Biomarker Decision Gates
• Chair: Levi Garraway, Roche
